CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Rhea-AI Summary
CervoMed (NASDAQ: CRVO) reported positive Phase 2b RewinD-LB results and regulatory alignment for a planned Phase 3 in dementia with Lewy bodies (DLB).
The company selected 50 mg TID neflamapimod for the Phase 3 (~300 patients) and expects multiple catalysts in H2 2026. Cash was $20.9M at year-end 2025 with an estimated ~six-month runway; full-year 2025 net loss was $27.0M.
Positive
- Positive Phase 2b RewinD-LB clinical results with biomarker correlation
- Regulatory alignment with FDA and global regulators on Phase 3 design
- Selected 50 mg TID stable crystal formulation for Phase 3
- ~300-patient planned global randomized Phase 3 trial
- Multiple patents issued in Europe, Japan, and China
- Inclusion of neflamapimod in the UK EXPERTS-ALS platform
Negative
- Year-end cash of $20.9M supports operations for ~six months
- Cash reduced from $38.9M to $20.9M year-over-year
- Full-year net loss $27.0M for 2025
- Grant revenue declined from $9.7M to $4.0M
- R&D expenses increased to $21.8M (higher personnel and CMC costs)
News Market Reaction – CRVO
On the day this news was published, CRVO gained 5.10%, reflecting a notable positive market reaction. Argus tracked a peak move of +12.6% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $43M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Select biotech peers show mixed moves, with some up and others down, suggesting stock-specific drivers rather than a uniform sector trend.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 10 | Q3 2025 earnings | Positive | -0.3% | Q3 2025 results plus FDA alignment on Phase 3 DLB design and runway update. |
| Aug 11 | Q2 2025 earnings | Positive | -3.5% | Q2 2025 results with strong RewinD-LB extension data and Phase 3 planning. |
| May 12 | Q1 2025 earnings | Positive | +7.2% | Q1 2025 results and positive 16-week RewinD-LB extension data with new trials. |
| Mar 17 | FY 2024 results | Positive | +40.5% | Full-year 2024 results highlighting strong RewinD-LB data and extended runway. |
| Nov 12 | Q3 2024 earnings | Neutral | -2.5% | Q3 2024 results with Phase 2b trial completion and topline timing guidance. |
Earnings updates with strong DLB data have sometimes triggered sharp gains, but reactions have been mixed, with several quarters seeing muted or negative moves despite positive clinical progress.
Over the past five earnings-related updates from Nov 2024 through Nov 2025, CervoMed has repeatedly paired financial results with advancing neflamapimod in DLB, including progression from Phase 2b data to concrete Phase 3 planning. Cash levels and runway have fluctuated, while net losses widened as R&D spending increased. Reactions ranged from a sharp +40.53% move on 2024 results to mild declines, showing that even encouraging trial updates have not always produced consistent price strength.
Historical Comparison
Across five prior earnings releases, CRVO’s average move was 8.26%, with reactions ranging from muted declines to a large rally when DLB data and runway updates were strongest.
Earnings updates have traced neflamapimod’s path from Phase 2b signals toward a single global Phase 3 DLB trial, alongside rising R&D spend and evolving cash runway disclosures.
Market Pulse Summary
The stock moved +5.1% in the session following this news. A strong positive reaction aligns with CervoMed’s pattern of occasionally large moves on earnings tied to DLB progress, such as the +40.53% jump in March 2024. However, the new results also highlight a cash balance of $20.9M and a net loss of $27.0M for 2025, pointing to financing needs around the planned ~300-patient Phase 3. Past mixed reactions suggest enthusiasm could fade if funding visibility does not improve.
Key Terms
phase 2b medical
phase 3 medical
new drug application regulatory
randomized, double-blind, placebo-controlled medical
clinical dementia rating-sum of boxes (cdr-sb) medical
cerebrospinal fluid medical
biomarkers medical
AI-generated analysis. Not financial advice.
Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026
Obtained alignment with FDA and global regulators for planned Phase 3 trial design in patients with DLB and selected Phase 3 formulation, dose and dosing regimen
Multiple potential catalysts anticipated in the second half of 2026, including initiation of the planned Phase 3 trial, topline data from Phase 2a ischemic stroke recovery trial, initial topline data from Phase 2a primary progressive aphasia trial, and initiation of EXPERTS-ALS trial in Amyotrophic Lateral Sclerosis
BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided corporate updates.
“CervoMed made significant strides in 2025 and early 2026 with its lead neflamapimod program in dementia with Lewy bodies (DLB). We reported positive and supportive Phase 2b RewinD-LB data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, obtained alignment with the U.S. Food and Drug Administration (FDA) and other global regulators on the design of our planned Phase 3 trial design in patients with DLB, and selected the neflamapimod formulation, dose and dosing regimen that will be used in the planned Phase 3 trial,” said John Alam, MD, Chief Executive Officer of CervoMed. “We are now looking ahead to a catalyst-driven 2026, including initiation of the planned Phase 3 trial evaluating neflamapimod in DLB in the second half of 2026, subject to available financing. In addition, we expect to report initial topline Phase 2a results from our other programs evaluating neflamapimod in both ischemic stroke recovery (RAS) and the non-fluent variant primary progressive aphasia (nfvPPA), along with initiation of the EXPERTS-ALS trial in amyotrophic lateral sclerosis (ALS), all during the second half of 2026 as well.”
Fourth Quarter 2025 and Recent Program Highlights
Dementia with Lewy Bodies
- CervoMed selected 50mg three times per day (TID) of a stable crystal form of neflamapimod produced using a new, controlled manufacturing process as the dose and dosing regimen that will be used for the Company’s planned Phase 3 trial in patients with DLB.
- CervoMed obtained alignment with the FDA on a proposed Phase 3 trial design to support a potential New Drug Application for neflamapimod in DLB in November 2025 and with other global regulators during the first quarter of 2026. Based on FDA feedback, CervoMed plans to initiate a single, global, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of neflamapimod in approximately 300 patients with DLB, subject to available funding. The trial will exclude patients who have historical evidence of AD co-pathology by brain imaging scan or cerebrospinal fluid sampling and will be further enriched for participants who do not have AD co-pathology by excluding patients with plasma ptau181 ≥ 21.0 pg/mL at screening. Participants will be randomized 1:1 to receive either oral neflamapimod or placebo for 32 weeks, followed by a neflamapimod only extension for 48 weeks. The primary endpoint will be worsening of global cognition and function as measured by change in the Clinical Dementia Rating-Sum of Boxes (CDR-SB). Secondary endpoints include the percentage of participants who have a greater than 1.5-point increase in CDR-SB and other well-established measures of cognitive and motor function. Assessments of key biomarkers of the neurodegenerative process will also be included.
- In a late-breaking oral session at CTAD Conference, clinical investigators shared the full results of the Phase 2b RewinD-LB trial evaluating neflamapimod for the treatment of DLB. The results of the trial demonstrated a significant and clinically meaningful effect on multiple outcomes in DLB patients, including on the primary outcome measure, change in CDR-SB, in the participants who received neflamapimod drug product that achieved expected and targeted plasma drug concentrations. These positive clinical outcomes were correlated with observed reductions in established biomarkers of neurodegeneration, supporting neflamapimod’s mode of action targeting the underlying DLB mechanism.
Amyotrophic Lateral Sclerosis (ALS)
- Neflamapimod was recently selected for inclusion in the EXPERTS-ALS platform in the United Kingdom (UK). EXPERTS-ALS facilitates rapid testing of potential treatments for ALS to identify promising drug candidates and potentially accelerate their path to regulatory approval. EXPERTS-ALS, funded by the UK government and UK-based charities, will conduct the clinical trial and CervoMed will provide drug product.
Corporate Updates
- During the fourth quarter of 2025 and first quarter of 2026, multiple patents related to neflamapimod were issued in Europe, Japan, and China, strengthening CervoMed’s global intellectual property portfolio supporting the development of neflamapimod for neurodegenerative disorders.
- In October 2025, Matthew Winton, Ph.D., joined CervoMed as Chief Commercial and Business Officer and David Quigley joined the Company’s Board of Directors.
Anticipated Milestones for 2026
- DLB: CervoMed plans to initiate a Phase 3 trial evaluating neflamapimod in patients with DLB in the second half of 2026, subject to obtaining sufficient funding. The Company will present additional data supporting its choice of patient population and dosing regimen for the trial at the AD/PD 2026 Scientific Conference taking place March 17-21, 2026, in Copenhagen, Denmark.
- RAS: CervoMed expects to complete enrollment in its ongoing Phase 2a RESTORE trial evaluating neflamapimod in patients recovering from acute ischemic stroke in mid-2026 and to report topline data from the trial in the second half of 2026.
- nfvPPA: CervoMed expects to complete enrollment in its ongoing Phase 2a trial evaluating neflamapimod in patients with nfvPPA in mid-2026. The Company also expects to report initial biomarker data from the trial in mid-2026 and initial topline clinical data from the trial in the second half of 2026.
- ALS: CervoMed expects initiation of the EXPERTS-ALS trial evaluating neflamapimod in patients with ALS by the end of 2026.
Full Year 2025 Financial Results
Cash Position: As of December 31, 2025, CervoMed had approximately
Grant Revenue: Grant revenue was approximately
Research and Development (R&D) Expenses: R&D expenses for the twelve months ended December 31, 2025, were approximately
General and Administrative (G&A) Expenses: G&A expenses were approximately
Net Loss: Net loss was approximately
About Neflamapimod
Neflamapimod is an investigational, orally administered small-molecule drug that readily crosses the blood–brain barrier and selectively inhibits the alpha isoform of p38 MAP kinase, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, recovery after ischemic stroke, and primary progressive aphasia.
In non-clinical studies, neflamapimod restored synaptic function within the basal forebrain cholinergic system, the brain region most affected in DLB. Across Phase 1 and 2 clinical trials involving more than 800 participants, the drug has been generally well tolerated and demonstrated consistent signals of efficacy. In the 91-patient Phase 2a AscenD-LB trial, neflamapimod significantly improved dementia severity and functional mobility in patients with DLB. Results from the 159-patient Phase 2b RewinD-LB trial, a 16-week randomized, double-blind, placebo-controlled trial followed by a 32-week open-label extension, further supported neflamapimod’s potential to deliver meaningful clinical benefit, improving both cognitive and functional outcomes and showing a positive effect on a key blood biomarker of neurodegeneration during the extension phase. Across both studies, the greatest benefits were observed in patients without AD co-pathology. Collectively, these findings underscore the therapeutic promise and scientific validity of neflamapimod as a potential treatment for DLB and other degenerative brain disorders.
About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology. The Company plans to initiate a global, pivotal Phase 3 trial in patients with DLB, enriched for those without AD co-pathology, in the second half of 2026, subject to available funding.
Forward-Looking Statements
This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the Company’s need to acquire sufficient funding, including funding for its planned Phase 3 trial; our anticipated cash runway; the therapeutic potential of neflamapimod in DLB or any other indication, including the degree of sustainability of any therapeutic effects and the plasma drug concentrations that may be achieved with neflamapimod treatment in any of the Company’s future clinical trials; the anticipated timing and achievement of clinical and development milestones, including the Company’s initiation of the Company’s planned Phase 3 trial in DLB patients and the announcement of any data therefrom; the anticipated data readouts from the Phase 2a trials in RAS and nfvPPA and the anticipated dosing of the first patient with neflamapimod in the EXPERTS-ALS trial; any other expected or implied benefits or results, including the extent (if any) to which neflamapimod may demonstrate efficacy or other clinical or biomarker improvements in patients; and expectations with respect to neflamapimod, including the timing of any regulatory submissions and potential approvals thereof, if any, in DLB or any other indication. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources, the availability of additional funds on acceptable terms, and the Company’s ability to continue as a going concern; the results of the Company’s clinical trials; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA or other regulators; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (SEC) on March 13, 2026, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.
Contacts
Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431
Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902
FAQ
When does CervoMed (CRVO) plan to start the Phase 3 trial in DLB and how large will it be?
What neflamapimod dose and formulation did CervoMed (CRVO) select for the planned Phase 3 in DLB?
How strong is CervoMed's (CRVO) cash runway and will it fund planned 2026 activities?
What did the Phase 2b RewinD-LB results reported by CervoMed (CRVO) show?
When will CervoMed (CRVO) report other 2026 clinical readouts for RAS, nfvPPA, and ALS programs?
